Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com
DCIS

Oncotype DX Breast DCIS Score® Test

It’s a clinically validated genomic test for patients with DCIS

Approximately 20% of all new breast cancers diagnosed in the United States are ductal carcinoma in situ (DCIS)1, but no two DCIS patients—or their tumors—are the same. The Oncotype DX Breast DCIS Score test looks at the unique biology of a patient’s tumor—so you can better personalize the treatment plan for each patient’s unique situation.

 

Guide patients to the right treatment using the right assessment

The Breast DCIS Score® test provides an individualized assessment for the risk of local recurrence. Performed on a tumor sample after a biopsy or surgery, the test looks at 12 cancer-related genes in your patient’s tumor—giving you information that clinical and pathologic factors alone can’t provide. In fact, the test shows that patients with similar clinical and pathologic features do not necessarily have the same local recurrence risk.2-4

The Breast DCIS Score test results include2-4:

  • An individualized prediction of the 10-year risk of any local recurrence (DCIS or invasive carcinoma) or an invasive local recurrence
  • An established baseline for consideration of absolute benefit from radiation therapy (XRT)
  • Quantitative ER and PR single-gene expression values
  • A patient-friendly summary page to help explain the results to your patients

See if your patient is eligible

Results your patients can relate to

The Breast DCIS Score report includes the DCIS Score® result, which is a number between 0 and 100.

  • Patients with a low risk estimate are likely to have a smaller absolute benefit from radiation therapy
  • Patients with a high risk estimate are likely to have a greater absolute benefit from radiation therapy

This numeric score makes it easy for patients to understand their level of risk. As a result, discussing treatment options with your patients is easier, and patients feel more confident about their decisions.

Evidence it works

Two validation studies—ECOG E5194 and the Ontario DCIS Cohort—confirm that the DCIS Score result predicts the 10-year risk of local recurrence.2-4 In addition, studies show that physicians regularly change treatment recommendations based on the test results.5,6

View more clinical evidence

Every patient deserves to know the feeling of greater certainty.

Coverage and financial assistance

Exact Sciences is committed to supporting patient access to the Oncotype DX Breast DCIS test to help your patients make informed decisions about their treatment.*

View more billing and coverage details

 

*The Oncotype DX Breast DCIS Score test is reported on claims with the unique proprietary laboratory analysis (PLA) code 0045U.

Icon order 

We make your ordering experience efficient. You can order tests through the physician portal and we’ll help you every step of the way.

Order a test